Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19-IL2 plus radiotherapy for limited metastatic NSCLC
NL-OMON27928Phase 2Recruiting
- Sponsor
- Maastricht University
- Start
- Nov 2019
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darleukin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Maastricht University. Primary endpoint: Progression-free survival at 1.5 years after randomization. Started Nov 2019; status: recruiting.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON27928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27928.